InnovaTV 301/ENGOT-Cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study Of Tisotumab Vedotin Versus Investigator’s Choice Of Chemotherapy In 2L Or 3L Recurrent Or Metastatic Cervical Cancer
ESGO eAcademy, Antonio Gonzalez-Martin,
410929
BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030), A Randomised Phase 3 Trial Of First-Line Atezolizumab With Bevacizumab And Platinum-Based Chemotherapy For Metastatic (Stage IVB), Persistent Or Recurrent Cervical Cancer
ESGO eAcademy, Ana Oaknin,
410928
Patient-Reported Outcomes From The Phase 3, Randomized, Double-Blind, Placebo-Controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 Study Of Pembrolizumab Plus Concurrent Chemoradiotherapy In Patients With High-Risk Locally Advanced Cervical Cancer
ESGO eAcademy, Sandro Pignata,
410926